Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19.


Journal

Journal of neurovirology
ISSN: 1538-2443
Titre abrégé: J Neurovirol
Pays: United States
ID NLM: 9508123

Informations de publication

Date de publication:
02 2021
Historique:
received: 20 10 2020
accepted: 14 01 2021
revised: 18 12 2020
pubmed: 3 2 2021
medline: 13 3 2021
entrez: 2 2 2021
Statut: ppublish

Résumé

As the SARS-COV-2 becomes a global pandemic, many researchers have a concern about the long COVID-19 complications. Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is a persistent, debilitating, and unexplained fatigue disorder. We investigated psychological morbidities such as CFS and post-traumatic stress disorder (PTSD) among survivors of COVID-19 over 6 months. All COVID-19 survivors from the university-affiliated hospital of Tehran, Iran, were assessed 6 months after infection onset by a previously validated questionnaire based on the Fukuda guidelines for CFS/EM and DSM-5 Checklist for PTSD (The Post-traumatic Stress Disorder Checklist for DSM-5 or PCL-5) to determine the presence of stress disorder and chronic fatigue problems. A total of 120 patients were enrolled. The prevalence rate of fatigue symptoms was 17.5%. Twelve (10%) screened positive for chronic idiopathic fatigue (CIF), 6 (5%) for CFS-like with insufficient fatigue syndrome (CFSWIFS), and 3 (2.5%) for CFS. The mean total scores in PCL-5 were 9.27 ± 10.76 (range:0-44), and the prevalence rate of PTSD was 5.8%. There was no significant association after adjusting between CFS and PTSD, gender, comorbidities, and chloroquine phosphate administration. The obtained data revealed the prevalence of CFS among patients with COVID-19, which is almost similar to CFS prevalence in the general population. Moreover, PTSD in patients with COVID-19 is not associated with the increased risk of CFS. Our study suggested that medical institutions should pay attention to the psychological consequences of the COVID-19 outbreak.

Identifiants

pubmed: 33528827
doi: 10.1007/s13365-021-00949-1
pii: 10.1007/s13365-021-00949-1
pmc: PMC7852482
doi:

Substances chimiques

Antiviral Agents 0
Drug Combinations 0
lopinavir-ritonavir drug combination 0
Oseltamivir 20O93L6F9H
Lopinavir 2494G1JF75
Hydroxychloroquine 4QWG6N8QKH
Ritonavir O3J8G9O825

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

154-159

Références

Arch Intern Med. 2007 Jun 25;167(12):1312-20
pubmed: 17592106
Arch Intern Med. 2009 Dec 14;169(22):2142-7
pubmed: 20008700
Lancet Psychiatry. 2015 Nov;2(11):1002-12
pubmed: 26544749
BMJ Open. 2017 Nov 13;7(11):e017521
pubmed: 29133321
Fatigue. 2017;5(4):215-230
pubmed: 30854252
Am J Transl Res. 2013;5(1):53-68
pubmed: 23390566
Med Hypotheses. 2020 Nov;144:110055
pubmed: 32758891
J Trauma Stress. 2015 Dec;28(6):489-98
pubmed: 26606250
Ann Intern Med. 1994 Dec 15;121(12):953-9
pubmed: 7978722
Nat Rev Immunol. 2005 Mar;5(3):243-51
pubmed: 15738954
Epidemiology. 2019 Nov;30(6):911-917
pubmed: 31584893
J Intern Med. 2011 Oct;270(4):327-38
pubmed: 21777306
Mil Med. 2016 Nov;181(11):e1515-e1531
pubmed: 27849485
J Inflamm Res. 2018 Mar 22;11:111-121
pubmed: 29606885
Vaccine. 2015 Nov 17;33(46):6173-7
pubmed: 26475444
Basic Clin Neurosci. 2020 Mar-Apr;11(2):179-184
pubmed: 32855777
Emerg Infect Dis. 2005 Aug;11(8):1297-300
pubmed: 16102324
Psychol Assess. 2016 Nov;28(11):1379-1391
pubmed: 26653052
BMC Neurol. 2011 Mar 24;11:37
pubmed: 21435231
J Transl Med. 2020 Feb 24;18(1):100
pubmed: 32093722
Sports Med. 2001;31(3):167-94
pubmed: 11286355

Auteurs

Leila Simani (L)

Skull Base Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Mahtab Ramezani (M)

Skull Base Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. drramezani23@gmail.com.

Ilad Alavi Darazam (IA)

Department of Infectious Diseases and Tropical Medicine, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Mastooreh Sagharichi (M)

Skull Base Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Mohammad Amin Aalipour (MA)

Skull Base Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Fatemeh Ghorbani (F)

Skull Base Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Hossein Pakdaman (H)

Brain Mapping Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH